Bay­er’s Blue­Rock now plans to bring Parkin­son’s cell ther­a­py straight to Phase 3 tri­al

Bay­er’s ex­per­i­men­tal Parkin­son’s dis­ease ther­a­py made from stem cells will soon en­ter late-stage stud­ies, mark­ing a key test for re­gen­er­a­tive med­i­cine in neu­ro­log­ic con­di­tions. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER